alk3

LDN193189 (LDN-193189) (DM 3189) is a selective BMP signaling inhibitor, inhibiting the transcriptional activity of ALK2 and ALK3 (IC50s: 0.8/0.8/5.3/16.7 nM for ALK1/2/3/6).

ALK2-IN-2 is a potent and selective inhibitor of activin receptor-like kinase 2 (ALK2) with an IC50 of 9 nM, demonstrating 700-fold higher inhibition of ALK2 compared to ALK3.

LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1/3 compared to other inhibitors.

ML347 (LDN 193719)(DN193719) is a highly specific ALK1/2 inhibitor ( IC50: 46/32 nM), and the selectivity for ALK2 is >300-fold than ALK3.

LDN-214117 is a potent and selective ALK2 inhibitor.

LDN-193189 2HCl (DM-3189 2HCl) is a selective BMP signaling inhibitor that inhibits ALK1,ALK2,ALK3 and ALK6, showing IC50s of 0.8 nM, 0.8 nM, 5.3 nM, and 16.7 nM, respectively, in kinase assays.LDN-193189 2HCl inhibited the transcriptional activity of BMP type I receptors in C2C12 cells, with IC50s of 5 nM and 30 nM, respectively. LDN-193189 2HCl inhibited the transcriptional activity of BMP type I receptors ALK2 and ALK3 in C2C12 cells, with IC50s of 5 nM and 30 nM, respectively, and was 200-fold more selective for BMP than for TGF-β.

LDN-193189 HCl (LDN193189 Hydrochloride) is a selective BMP type I receptor kinases inhibitor.

Vactosertib (EW-7197) is an orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase 5 (ALK5), with potential antineoplastic activity.

M4K2234 (Compound 26b) is a selective inhibitor of ALK2, displaying IC50 values of 5 nM for ALK2 and 2144 nM for ALK5. As a chemical probe for ALK1 and ALK2 kinases, it is used in mechanistic studies of BMP signaling and in cancer research where dysregulated ALK2 activity is implicated. Its high selectivity profile supports targeted investigations into ALK-mediated pathways.

dALK-3 is a degrader of anaplastic lymphoma kinase (ALK) that effectively induces the degradation of EML4-ALK with a DC50 of 0.182 μM. It exhibits significant antiproliferative activity against H3122 cells and is applicable for tumor research.

DMH-1 is a potent and selective Bone Morphogenetic Protein (BMP) inhibitor.

Dorsomorphin (BML-275) is an AMPK inhibitor (Ki=109 nM) that is selective and ATP-competitive. Dorsomorphin inhibits the BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin induces autophagy, and possesses antitumor activity.

K 02288 is a novel small molecule inhibitor of ALK1/2/3/6.

TP-0427736 is a novel potent and selective ALK5 inhibitor (IC50: 2.72 nM). P0427736 was 300-fold higher than the inhibitory effect on ALK3. TP0427736 reduces TGF-β induced growth inhibition in human outer root sheath cells and elongates the anagen phase i

DMH2 is a selective BMP type I receptor (ALK2/ALK3) inhibitor. DMH2 inhibits the proliferation of lung cancer cell lines and induces cell death. DMH2 can be used in research on tumors, stem cell differentiation, and bone formation.

TP0427736 hydrochloride is a novel and selective ALK5 inhibitor with an IC50 of 2.72 nM, capable of inhibiting Smad2/3 phosphorylation in A549 cells, reducing TGF-β-induced growth inhibition of human root sheath cells, and prolonging the anagen phase of mouse hair follicles.

Dorsomorphin dihydrochloride (BML-275 2HCl) is a potent, selective and ATP-competitive AMPK inhibitor (Ki: 109 nM) and does not exhibit significant activity on structurally related kinases.

LDN-193189 Tetrahydrochloride (DM-3189 Tetrahydrochloride) is a selective inhibitor of BMP type I receptors, inhibiting ALK2 and ALK3 (IC₅₀ = 5/30 nM), with weaker activity against ALK4, ALK5, and ALK7, and can be used for research into progressive osseous fibrodysplasia.

THR-123 is an orally active ALK3 peptide agonist. It binds relatively weakly to ALK2 and does not bind to ALK6. THR-123 can inhibit inflammation, apoptosis (cell death), and epithelial-mesenchymal transition, as well as reverse fibrosis already formed in five different acute and chronic kidney injury mouse models. THR-123 is applicable for research on renal fibrosis.